Abstract 14652: Baxdrostat for Resistant Hypertension: A Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials
A meta-analysis of five RCTs shows baxdrostat significantly reduces SBP and DBP in resistant hypertension via selective aldosterone synthase inhibition, sparing cortisol, supporting its role as a promising novel therapeutic option.